がん診断における人工知能（AI）の世界市場：洞察、競合情勢、市場予測：2032年

がん診断における人工知能の市場規模は、2024年に10億4,918万米ドルとなりました。同市場は、2025年から2032年までの予測期間中に11.16％のCAGRで拡大し、2032年には24億3,432万米ドルに達すると予測されています。がん罹患率の上昇が高度な診断ソリューションの需要に拍車をかけており、人工知能（AI）を早期発見と精密腫瘍学のための重要なツールとして位置付けています。CTスキャン、MRI、マンモグラム、病理スライドなどの医療用画像診断モダリティとAIの統合が進むことで、診断精度が大幅に向上し、人為的ミスが最小限に抑えられ、がんの発見が加速され、最終的には患者の転帰が改善されます。

主要な市場参入企業は、AI主導のがん診断ポートフォリオを強化し、技術力を拡大するために、製品の発売、合併、買収、提携などの戦略的イニシアティブを通じて取り組みを強化しています。これらの複合的な要因が、がん診断におけるAI市場の世界の大幅な成長を促進し、がん検出におけるアクセシビリティ、効率性、信頼性を向上させ、2025年から2032年までの予測期間を通じて腫瘍学ケアに革命をもたらすと考えられています。

国際がん研究機関（IARC、2024年）の最新データによると、世界の新規がん患者数は2022年には2,000万人と推定され、2045年には3,260万人に増加すると予測されています。乳がんは2022年に世界で約230万人の新規症例を占め、2045年には336万人に増加すると予測されています。

このような世界のがん罹患率の上昇は、先進的な診断ソリューションに対する需要を促進しており、人工知能（AI）は治療成績の向上に不可欠な早期かつ正確な発見において極めて重要な役割を果たしています。生検や手作業による画像解釈などの従来の診断方法は、時間がかかることが多く、人為的ミスが起こりやすくなります。対照的に、AIを搭載したソリューションは、MRI、CTスキャン、病理組織スライドなどの医療用画像診断モダリティから得られる膨大なデータセットを分析することで、診断精度を高め、検出を自動化し、診断を迅速化します。AIはさらに、ゲノムデータや患者データと統合し、腫瘍医による個別化治療計画の立案をサポートします。

AIと医療用画像の統合は、精度、効率、早期発見を向上させることで、がん診断に革命をもたらしています。ディープラーニングアルゴリズムとコンピュータビジョンを活用したAI主導の画像診断ソリューションは、人間の観察者では見落とされる可能性のあるパターンや異常を特定することができます。これらの技術は、画像のセグメンテーション、病変の検出、腫瘍の分類を強化し、より早く正確な診断を可能にします。高度なAIモデルは、より高い感度と特異性で良性腫瘍と悪性腫瘍を区別し、偽陽性を減らし、不必要な生検を最小限に抑えることができます。さらに、AIを搭載したツールは、腫瘍の進行のモニタリング、治療反応の評価、疾患の再発予測を支援し、腫瘍医が個別の治療に関して十分な情報に基づいた決定を下すことを可能にします。

当レポートでは、世界のがん診断における人工知能（AI）市場について調査し、市場の概要とともに、コンポーネント別、がんタイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 がん診断における人工知能市場レポートのイントロダクション

第2章 がん診断における人工知能市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 がん診断における人工知能市場の主な要因分析

• がん診断における人工知能市場の促進要因
• がん診断における人工知能市場の抑制要因と課題
• がん診断における人工知能市場の機会

第6章 がん診断における人工知能市場におけるポーターのファイブフォース分析

第7章 がん診断における人工知能市場の評価

• コンポーネント別
• がんタイプ別
• エンドユーザー別
• 地域別

第8章 がん診断における人工知能市場の企業および製品プロファイル

• iCAD, Inc.
• ibex-ai
• Roche Diagnostics
• Kheiron Medical Technologies Limited
• MVision AI Inc.
• Siemens Healthineers AG
• GE HealthCare
• NVIDIA Corporation
• Digital Diagnostics Inc.
• IBM Corporation
• Azra AI
• ConcertAI
• PathAI
• Median Technologies
• Paige AI Inc.
• Therapixel
• Flatiron
• Freenome Holdings Inc.
• Onc.AI
• Sonrai Analytics

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Artificial Intelligence in Cancer Diagnostics Market in Global (2022-2032)
• Table 3: Artificial Intelligence in Cancer Diagnostics Market in Global by Component (2022-2032)
• Table 4: Artificial Intelligence in Cancer Diagnostics Market in Global by Cancer Type (2022-2032)
• Table 5: Artificial Intelligence in Cancer Diagnostics Market in Global by End-User (2022-2032)
• Table 6: Artificial Intelligence in Cancer Diagnostics Market in Global by Geography (2022-2032)
• Table 7: Artificial Intelligence in Cancer Diagnostics Market in North America (2022-2032)
• Table 8: Artificial Intelligence in Cancer Diagnostics Market in the United States (2022-2032)
• Table 9: Artificial Intelligence in Cancer Diagnostics Market in Canada (2022-2032)
• Table 10: Artificial Intelligence in Cancer Diagnostics Market in Mexico (2022-2032)
• Table 11: Artificial Intelligence in Cancer Diagnostics Market in Europe (2022-2032)
• Table 12: Artificial Intelligence in Cancer Diagnostics Market in France (2022-2032)
• Table 13: Artificial Intelligence in Cancer Diagnostics Market in Germany (2022-2032)
• Table 14: Artificial Intelligence in Cancer Diagnostics Market in United Kingdom (2022-2032)
• Table 15: Artificial Intelligence in Cancer Diagnostics Market in Italy (2022-2032)
• Table 16: Artificial Intelligence in Cancer Diagnostics Market in Spain (2022-2032)
• Table 17: Artificial Intelligence in Cancer Diagnostics Market in the Rest of Europe (2022-2032)
• Table 18: Artificial Intelligence in Cancer Diagnostics Market in Asia-Pacific (2022-2032)
• Table 19: Artificial Intelligence in Cancer Diagnostics Market in China (2022-2032)
• Table 20: Artificial Intelligence in Cancer Diagnostics Market in Japan (2022-2032)
• Table 21: Artificial Intelligence in Cancer Diagnostics Market in India (2022-2032)
• Table 22: Artificial Intelligence in Cancer Diagnostics Market in Australia (2022-2032)
• Table 23: Artificial Intelligence in Cancer Diagnostics Market in South Korea (2022-2032)
• Table 24: Artificial Intelligence in Cancer Diagnostics Market in Rest of Asia-Pacific (2022-2032)
• Table 25: Artificial Intelligence in Cancer Diagnostics Market in the Rest of the World (2022-2032)
• Table 26: Artificial Intelligence in Cancer Diagnostics Market in the Middle East (2022-2032)
• Table 27: Artificial Intelligence in Cancer Diagnostics Market in Africa (2022-2032)
• Table 28: Artificial Intelligence in Cancer Diagnostics Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Artificial Intelligence in Cancer Diagnostics Market in Global (2022-2032)
• Figure 3: Artificial Intelligence in Cancer Diagnostics Market in Global by Component (2022-2032)
• Figure 4: Artificial Intelligence in Cancer Diagnostics Market in Global by Cancer Type (2022-2032)
• Figure 5: Artificial Intelligence in Cancer Diagnostics Market in Global by End-User (2022-2032)
• Figure 6: Artificial Intelligence in Cancer Diagnostics Market in Global by Geography (2022-2032)
• Figure 7: Artificial Intelligence in Cancer Diagnostics Market in North America (2022-2032)
• Figure 8: Artificial Intelligence in Cancer Diagnostics Market in the United States (2022-2032)
• Figure 9: Artificial Intelligence in Cancer Diagnostics Market in Canada (2022-2032)
• Figure 10: Artificial Intelligence in Cancer Diagnostics Market in Mexico (2022-2032)
• Figure 11: Artificial Intelligence in Cancer Diagnostics Market in Europe (2022-2032)
• Figure 12: Artificial Intelligence in Cancer Diagnostics Market in France (2022-2032)
• Figure 13: Artificial Intelligence in Cancer Diagnostics Market in Germany (2022-2032)
• Figure 14: Artificial Intelligence in Cancer Diagnostics Market in United Kingdom (2022-2032)
• Figure 15: Artificial Intelligence in Cancer Diagnostics Market in Italy (2022-2032)
• Figure 16: Artificial Intelligence in Cancer Diagnostics Market in Spain (2022-2032)
• Figure 17: Artificial Intelligence in Cancer Diagnostics Market in the Rest of Europe (2022-2032)
• Figure 18: Artificial Intelligence in Cancer Diagnostics Market in Asia-Pacific (2022-2032)
• Figure 19: Artificial Intelligence in Cancer Diagnostics Market in China (2022-2032)
• Figure 20: Artificial Intelligence in Cancer Diagnostics Market in Japan (2022-2032)
• Figure 21: Artificial Intelligence in Cancer Diagnostics Market in India (2022-2032)
• Figure 22: Artificial Intelligence in Cancer Diagnostics Market in Australia (2022-2032)
• Figure 23: Artificial Intelligence in Cancer Diagnostics Market in South Korea (2022-2032)
• Figure 24: Artificial Intelligence in Cancer Diagnostics Market in Rest of Asia-Pacific (2022-2032)
• Figure 25: Artificial Intelligence in Cancer Diagnostics Market in the Rest of the World (2022-2032)
• Figure 26: Artificial Intelligence in Cancer Diagnostics Market in the Middle East (2022-2032)
• Figure 27: Artificial Intelligence in Cancer Diagnostics Market in Africa (2022-2032)
• Figure 28: Artificial Intelligence in Cancer Diagnostics Market in South America (2022-2032)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Market Opportunities
• Figure 32: PORTER'S Five Force Analysis

Artificial Intelligence (AI) in Cancer Diagnostics Market by Component (Software and Services), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Brain & Nervous System Cancers, and Others), End-User (Hospitals, Diagnostic Centre, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cancer incidence rates, increase integration of AI with medical imaging for cancer diagnostics, increase in strategic activities among the key market players across the globe.

The artificial intelligence in cancer diagnostics market was valued at USD 1,049.18 million in 2024, growing at a CAGR of 11.16% during the forecast period from 2025 to 2032 to reach USD 2,434.32 million by 2032. The rising incidence of cancer is fueling the demand for advanced diagnostic solutions, positioning Artificial Intelligence (AI) as a vital tool for early detection and precision oncology. The growing integration of AI with medical imaging modalities such as CT scans, MRIs, mammograms, and pathology slides significantly improves diagnostic accuracy, minimizes human error, and accelerates cancer detection, ultimately enhancing patient outcomes.

Major market players are intensifying their efforts through strategic initiatives, including product launches, mergers, acquisitions, and collaborations, to strengthen their AI-driven cancer diagnostic portfolios and expand their technological capabilities. These combined factors are poised to drive substantial growth in the global AI in the cancer diagnostics market, enhancing accessibility, efficiency, and reliability in cancer detection and revolutionizing oncology care throughout the forecast period from 2025 to 2032.

Artificial Intelligence (AI) in Cancer Diagnostics Market Dynamics:

According to the latest data from the International Agency for Research on Cancer (IARC, 2024), the estimated number of new cancer cases worldwide was 20 million in 2022, with projections indicating a rise to 32.6 million by 2045. Breast cancer accounted for approximately 2.3 million new cases globally in 2022, a figure expected to increase to 3.36 million by 2045.

This growing global cancer burden is driving demand for advanced diagnostic solutions, with Artificial Intelligence (AI) playing a pivotal role in early and accurate detection crucial for improving treatment outcomes. Traditional diagnostic methods, such as biopsies and manual interpretation of imaging, are often time-consuming and prone to human error. In contrast, AI-powered solutions enhance diagnostic precision, automate detection, and accelerate diagnosis by analyzing vast datasets from medical imaging modalities, including MRIs, CT scans, and histopathology slides. AI further integrates with genomic and patient data, supporting oncologists in devising personalized treatment plans.

The integration of AI with medical imaging is revolutionizing cancer diagnostics by improving accuracy, efficiency, and early detection. AI-driven imaging solutions, leveraging deep learning algorithms and computer vision, can identify patterns and anomalies that might be overlooked by human observers. These technologies enhance image segmentation, lesion detection, and tumor classification, allowing for earlier and more precise diagnoses. Advanced AI models can differentiate between benign and malignant tumors with higher sensitivity and specificity, reducing false positives and minimizing unnecessary biopsies. Additionally, AI-powered tools assist in monitoring tumor progression, evaluating treatment responses, and predicting disease recurrence, enabling oncologists to make well-informed decisions regarding individualized care.

Strategic initiatives by key market players are further propelling the growth of the AI in cancer diagnostics market. For example, in September 2024, Roche expanded its digital pathology platform by integrating over 20 advanced AI algorithms from eight new collaborators. This move facilitated through Roche's navify(R) Digital Pathology enterprise software, aims to enhance cancer research and diagnostic capabilities by providing pathologists with seamless access to cutting-edge AI innovations.

Despite these advancements, certain challenges persist. Limited data availability and quality pose significant hurdles, as AI models require large, diverse, and high-quality datasets for optimal performance. Inconsistencies, biases, and restricted access to comprehensive patient data can undermine model accuracy and reliability. Furthermore, stringent regulatory requirements and ethical considerations may slow market growth.

Overall, the combination of rising cancer prevalence, technological innovations, and strategic industry activities is expected to drive significant growth in the global AI in cancer diagnostics market during the forecast period from 2025 to 2032.

Artificial Intelligence (AI) in Cancer Diagnostics Market Segment Analysis:

Artificial Intelligence in Cancer Diagnostics Market by Component (Software and Services), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Brain & Nervous System Cancers, and Others), End-User (Hospitals, Diagnostic Centre, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the component segment of the artificial intelligence (AI) in cancer diagnostics market, the software category is expected to hold a significant share in 2024. This category serves as a key growth driver, revolutionizing how cancer is detected, analyzed, and managed. AI-powered software solutions are enhancing diagnostic accuracy, improving workflow efficiency, and reducing the workload on healthcare professionals. By leveraging deep learning and machine learning algorithms, these platforms analyze vast amounts of medical imaging data including MRIs, CT scans, and histopathology slides facilitating faster and more precise detection of cancerous lesions. In addition to early abnormality detection, AI software reduces false positives and negatives, thereby increasing diagnostic confidence.

AI-driven software also integrates with electronic health records (EHRs) and genomic data, supporting personalized cancer diagnostics and treatment recommendations tailored to patients' genetic and clinical profiles. The rise of cloud-based AI solutions further enhances accessibility by enabling remote diagnostics and seamless collaboration among oncologists, radiologists, and pathologists across various healthcare institutions.

Continuous advancements in AI algorithms, along with growing regulatory approvals for AI-based diagnostic software, are accelerating market adoption. Leading technology companies and healthcare providers are investing heavily in AI-driven software through strategic partnerships, acquisitions, and new product launches to strengthen their market presence. For example, in October 2024, Owkin the first end-to-end AI-biotech company utilizing advanced causal AI for precision drug discovery, development, and diagnostics launched MSIntuit(R) CRC v2, a next-generation AI software solution aimed at transforming colorectal cancer (CRC) detection and treatment. Initially introduced as a Research Use Only (RUO) product in the U.S., this solution was integrated into Roche's navify(R) Digital Pathology enterprise software to enhance diagnostic capabilities.

These technological advancements, combined with increasing investments and supportive regulatory environments, are expected to propel the software segment's growth, thereby boosting the overall global AI in cancer diagnostics market during the forecast period.

North America is expected to dominate the overall artificial intelligence in cancer diagnostics market:

North America is projected to hold the largest share of Artificial Intelligence (AI) in the Cancer Diagnostics market in 2024. This dominance is attributed to the region's high cancer prevalence, growing demand for advanced diagnostic solutions, strong government support, and substantial investments in AI-driven healthcare technologies. The presence of major AI developers and leading medical imaging companies further fuels market growth. The integration of AI with electronic health records (EHRs), precision medicine, and digital pathology is enhancing the efficiency and accuracy of cancer detection and diagnosis across the region.

According to recent data from the International Agency for Research on Cancer (IARC, 2024), North America recorded an estimated 2.67 million new cancer cases in 2022, with projections rising to 3.83 million by 2045. Breast cancer, a significant contributor to the cancer burden, accounted for approximately 306,000 new cases in 2022, with an expected increase to 384,000 cases by 2045. AI-powered diagnostic solutions are playing a crucial role in breast cancer detection by analyzing mammograms, ultrasounds, and MRI scans with remarkable precision. These technologies significantly reduce false positives and negatives, thereby improving diagnostic confidence. Machine learning algorithms are capable of detecting subtle imaging patterns that may elude human radiologists, leading to earlier and more accurate diagnoses. Furthermore, AI enhances risk assessment, tumor classification, and personalized treatment planning by integrating imaging data with genomic and clinical information.

The North American market is further bolstered by increasing strategic activities among key industry players, including mergers, acquisitions, regulatory approvals, and new product launches. These initiatives accelerate technological advancements, expand product portfolios, and strengthen market presence, enabling the introduction of innovative AI-driven solutions for cancer detection and treatment. For example, in October 2023, Philips partnered with Quibim, a specialist in imaging biomarkers, to launch AI-powered imaging and reporting solutions for Magnetic Resonance (MR) prostate screenings. Such collaborations are instrumental in advancing diagnostic capabilities and meeting the region's growing healthcare demands.

Overall, the combination of rising cancer incidence, technological innovation, supportive regulatory frameworks, and strategic industry initiatives is expected to propel the AI in cancer diagnostics market in North America during the forecast period from 2025 to 2032.

Artificial Intelligence in Cancer Diagnostics Market Key Players:

Some of the key market players operating in the artificial intelligence in cancer diagnostics market include iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, and others.

Recent Developmental Activities in the Artificial Intelligence in Cancer Diagnostics Market:

• In August 2023, MVision AI announced the release of version 1.2.4 of its guideline-based automatic segmentation service. This latest software update introduces new contouring models and advanced Region-Of-Interest (ROI) operations, aiming to enhance the accuracy and efficiency of cancer radiotherapy planning. The improved contouring capabilities are designed to standardize treatment protocols and significantly reduce the time to treatment, ultimately improving patient care and streamlining clinical workflows in oncology.
• In January 2023, Paige AI Inc. announced a collaboration with Microsoft to leverage artificial intelligence (AI) in analyzing digital pathology images. The partnership aims to develop and deliver a new generation of clinical applications and computational biomarkers to transform cancer diagnosis and enhance patient care. As part of this collaboration, Microsoft made a strategic investment in Paige to accelerate the development and deployment of life-saving AI-powered diagnostic solutions, further advancing innovation in oncology.

Key Takeaways From the Artificial Intelligence in Cancer Diagnostics Market Report Study

• Market size analysis for current artificial intelligence in cancer diagnostics size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the artificial intelligence in the cancer diagnostics market.
• Various opportunities available for the other competitors in the artificial intelligence in cancer diagnostics market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current artificial intelligence in cancer diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for artificial intelligence in cancer diagnostics market growth in the coming future?

Target Audience Who Can Benefited From This Artificial Intelligence in Cancer Diagnostics Market Report Study

• Artificial intelligence in cancer diagnostics product providers
• Research organizations and consulting companies
• Artificial intelligence in cancer diagnostics -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in artificial intelligence in cancer diagnostics
• Various end-users who want to know more about artificial intelligence in the cancer diagnostics market and the latest technological developments in artificial intelligence the cancer diagnostics market.

Frequently Asked Questions for the Artificial Intelligence in Cancer Diagnostics Market:

1. What is artificial intelligence in cancer diagnostics?

• Artificial Intelligence (AI) in cancer diagnostics refers to the use of advanced machine learning algorithms and deep learning models to analyze medical data, such as imaging, pathology slides, and genomic information, for early detection, accurate diagnosis, and treatment planning of cancer. It enhances efficiency, reduces human error, and enables personalized medicine to improve patient outcomes.

2. What is the market for artificial intelligence in cancer diagnostics?

• The artificial intelligence in cancer diagnostics market was valued at USD 1,049.18 million in 2024, growing at a CAGR of 11.16% during the forecast period from 2025 to 2032 to reach USD 2,434.32 million by 2032.

3. What are the drivers for the global artificial intelligence in cancer diagnostics market?

• The rising cancer incidence rates are driving the demand for advanced diagnostic solutions, making Artificial Intelligence (AI) a crucial tool in early detection and precision oncology. The increasing integration of AI with medical imaging, including CT scans, MRIs, mammograms, and pathology slides, enhances diagnostic accuracy, reduces human error, and speeds up cancer detection, improving patient outcomes. Additionally, key market players are actively engaging in strategic activities such as product launches, mergers, acquisitions, and collaborations to enhance AI-driven cancer diagnostic solutions, expanding their market reach and technological capabilities. These combined factors are expected to significantly propel the global AI in the cancer diagnostics market by increasing accessibility, efficiency, and reliability in cancer detection, ultimately transforming oncology care during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global artificial intelligence in cancer diagnostics market?

• Some of the key market players operating in the artificial intelligence in cancer diagnostics are iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, and others.

5. Which region has the highest share in global artificial intelligence in cancer diagnostics market?

• North America is expected to account for the highest proportion of artificial intelligence in cancer diagnostics market in 2024, out of all regions. The region has a high prevalence of cancer, driving the demand for advanced diagnostic solutions. Additionally, strong government support, substantial investments in AI-driven healthcare technologies, and the presence of major AI and medical imaging companies contribute to market growth. The integration of AI with electronic health records (EHRs), precision medicine, and digital pathology further enhances cancer detection and diagnosis. Moreover, increasing collaborations between AI developers and healthcare institutions, along with favorable regulatory policies, are accelerating AI adoption, solidifying North America's leadership in the market.

Table of Contents

1. Artificial Intelligence in Cancer Diagnostics Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Artificial Intelligence in Cancer Diagnostics Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Artificial Intelligence in Cancer Diagnostics Market Key Factors Analysis

• 5.1. Artificial Intelligence in Cancer Diagnostics Market Drivers
  • 5.1.1. The rising cancer incidence rates
  • 5.1.2. Increase integration of AI with medical imaging for cancer diagnostics
  • 5.1.3. Increase in strategic activities among the key market players across the globe.
• 5.2. Artificial Intelligence in Cancer Diagnostics Market Restraints and Challenges
  • 5.2.1. Limited data availability and quality
  • 5.2.2. Strict regulatory and ethical concerns
• 5.3. Artificial Intelligence in Cancer Diagnostics Market Opportunities
  • 5.3.1. The rise of cloud computing and AI-based SaaS (Software as a Service) models

6. Artificial Intelligence in Cancer Diagnostics Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Artificial Intelligence in Cancer Diagnostics Market Assessment

• 7.1. By Component
  • 7.1.1. Software
  • 7.1.2. Services
• 7.2. By Cancer Type
  • 7.2.1. Breast Cancer
  • 7.2.2. Lung Cancer
  • 7.2.3. Colorectal Cancer
  • 7.2.4. Prostate Cancer
  • 7.2.5. Brain & Nervous System Cancers
  • 7.2.6. Others
• 7.3. By End-User
  • 7.3.1. Hospitals
  • 7.3.2. Diagnostic Centre
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.1.2. Canada Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.1.3. Mexico Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
  • 7.4.2. Europe
    • 7.4.2.1. France Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.2.2. Germany Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.2.3. United Kingdom Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.2.4. Italy Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.2.5. Spain Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.2.6. Rest of Europe Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.3.2. Japan Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.3.3. India Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.3.4. Australia Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.3.5. South Korea Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.3.6. Rest of Asia-Pacific Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.4.2. Africa Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)
    • 7.4.4.3. South America Artificial Intelligence in Cancer Diagnostics Market Size in USD Million (2022-2032)

8. Artificial Intelligence in Cancer Diagnostics Market Company and Product Profiles

• 8.1. iCAD, Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. ibex-ai
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Roche Diagnostics
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Kheiron Medical Technologies Limited
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. MVision AI Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Siemens Healthineers AG
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. GE HealthCare
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. NVIDIA Corporation
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Digital Diagnostics Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. IBM Corporation
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Azra AI
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. ConcertAI
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. PathAI
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Median Technologies
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Paige AI Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Therapixel
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Flatiron
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Freenome Holdings Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Onc.AI
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Sonrai Analytics
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us